The translation of product concept to bone products: a partnership of therapeutic effectiveness and commercialization.

The fields of tissue engineering and regenerative medicine have the capacity to substantially impact clinical care through the introduction of new products that can address unmet clinical needs, or significantly improve on present therapies. These products will be developed through the demonstration of therapeutic effectiveness, adequate safety, and meeting regulatory requirements. The technology used in the product will dictate the product development and manufacturing costs; the regulatory pathway; and the time taken to complete clinical trials, gain regulatory approval, and become commercialized. A comparison of the required investment of time and funds, with the potential revenue generated, allows for a determination of the likely commercialization opportunity. Ultimately, the long-term success of a product will be dependent on its clinical effectiveness and commercial viability.

[1]  E Dantzer,et al.  Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. , 2001, British Journal of Plastic Surgery.

[2]  Steven S. Oh,et al.  Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. , 2010, Tissue engineering. Part B, Reviews.

[3]  V. Rosen,et al.  Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. , 1998, Clinical orthopaedics and related research.

[4]  Vicki Rosen,et al.  BMP2 signaling in bone development and repair. , 2009, Cytokine & growth factor reviews.

[5]  Michael J Lysaght,et al.  Tissue engineering: the end of the beginning. , 2004, Tissue engineering.

[6]  J. M. Badura,et al.  A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft) , 2007, International Orthopaedics.

[7]  J. Mansbridge,et al.  Tissue-Engineered Skin Substitutes , 2020, Technology in Practical Dermatology.

[8]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[9]  M. Auletta,et al.  Acute excisional wounds treated with a tissue-engineered skin (Apligraf). , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[10]  C. Ohlsson,et al.  Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. , 1994, The New England journal of medicine.

[11]  Gerald R. Williams,et al.  Complications of Thermal Capsulorrhaphy of the Shoulder , 2001, The Journal of bone and joint surgery. American volume.